Dorsal striatal volumes in never-treated patients with first-episode schizophrenia before and during acute treatment

Schizophrenia Research

Volumn 169, Issue 1-3, 2015, Pages 89-94

  Emsley, Robin ^a   Asmal, Laila ^a   du Plessis, Stéfan ^a   Chiliza, Bonginkosi ^a   Kidd, Martin ^b   Carr, Jonathan ^a   Vink, Matthijs ^c  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antipsychotics; Caudate; Putamen; Schizophrenia; Striatum

Indexed keywords

FLUPENTIXOL DECANOATE; RISPERIDONE; FLUPENTIXOL; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BRAIN SIZE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LEARNING; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROBLEM SOLVING; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; REASONING; SCHIZOPHRENIA; THINKING; TREATMENT OUTCOME; COMPARATIVE STUDY; DRUG EFFECTS; IMAGE PROCESSING; ORGAN SIZE; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS; SOFTWARE; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; CAUDATE NUCLEUS; DOUBLE-BLIND METHOD; FEMALE; FLUPENTHIXOL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; ORGAN SIZE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; PUTAMEN; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOFTWARE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84953837706     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.09.014     Document Type: Article

References (45)

1. Addington D., Addington J., Maticka-Tyndale E. Assessing depression in schizophrenia: the calgary depression scale. Br. J. Psychiatry Suppl. 1993, 22:S39-S44.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC. 4 Text revision ed.
3. Bazire S. Psychotropic Drug Directory. HealthComm UK Ltd, A Schofield Healthcare Media Company, Suite 3.1, 36 Upperkirkgate, Aberdeen 2010.
4. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 1995, 57(1):289-300.
5. Birchwood M., Smith J., Drury V., Healy J., Macmillan F., Slade M. A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr. Scand. 1994, 89(1):62-67.
6. Brandt G.N., Bonelli R.M. Structural neuroimaging of the basal ganglia in schizophrenic patients: a review. Wien. Med. Wochenschr. 2008, 158:84-90.
7. Cahn W., Hulshoff Pol H.E., Bongers M., Schnack H.G., Mandl R.C., van Haren N.E., Durston S., Koning H., Van Der Linden J.A., Kahn R.S. Brain morphology in antipsychotic-naive schizophrenia: a study of multiple brain structures. Br. J. Psychiatry Suppl. 2002, 43:s66-s72.
8. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogerts B., Wu H., Kinon B., Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am. J. Psychiatry 1994, 151:1430-1436.
9. Chemerinski E., Byne W., Kolaitis J.C., Glanton C.F., Canfield E.L., Newmark R.E., Haznedar M.M., Novakovic V., Chu K.W., Siever L.J., Hazlett E.A. Larger putamen size in antipsychotic-naive individuals with schizotypal personality disorder. Schizophr. Res. 2013, 143:158-164.
10. Chouinard G., Margolese H.C. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr. Res. 2005, 76:247-265.
11. Corson P.W., Nopoulos P., Andreasen N.C., Heckel D., Arndt S. Caudate size in first-episode neuroleptic-naive schizophrenic patients measured using an artificial neural network. Biol. Psychiatry 1999, 46:712-720.
12. Dale A.M., Fischl B., Sereno M.I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. NeuroImage 1999, 9:179-194.
13. DeLisi L.E., Hoff A.L., Schwartz J.E., Shields G.W., Halthore S.N., Gupta S.M., Henn F.A., Anand A.K. Brain morphology in first-episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study. Biol. Psychiatry 1991, 29:159-175.
14. Dieset I., Haukvik U.K., Melle I., Røssberg J.I., Ueland T., Hope S., Dale A.M., Djurovic S., Aukrust P., Agartz I., Andreassen O.A. Association between altered brain morphology and elevated peripheral endothelial markers-implications for psychotic disorders. Schizophr. Res. 2015, 161(2-3):222-228.
15. Doorduin J., de Vries E.F., Willemsen A.T., de Groot J.C., Dierckx R.A., Klein H.C. Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med. 2009, 50:1801-1807.
16. Ebdrup B.H., Norbak H., Borgwardt S., Glenthoj B. Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review. Curr. Med. Chem. 2013, 20:438-447.
17. Ellison-Wright I., Glahn D.C., Laird A.R., Thelen S.M., Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am. J. Psychiatry 2008, 165:1015-1023.
18. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?. J. Psychiatr. Res. 1982, 17:319-334.
19. First M.B., Spitzer R.L.G.M., Williams L.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P). 2nd. New York, New York State Psychiatric Institute. Biom. Res. 1994.
20. Glenthoj A., Glenthoj B.Y., Mackeprang T., Pagsberg A.K., Hemmingsen R.P., Jernigan T.L., Baare W.F. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res. 2007, 154:199-208.
21. Glickman M.E., Rao S.R., Schultz M.R. False discovery rate control is a recommended alternative to bonferroni-type adjustments in health studies. J. Clin. Epidemiol. 2014, 67(8):850-857.
22. Goldman A.L., Pezawas L., Mattay V.S., Fischl B., Verchinski B.A., Zoltick B., Weinberger D.R., Meyer-Lindenberg A. Heritability of brain morphology related to schizophrenia: a large-scale automated magnetic resonance imaging segmentation study. Biol. Psychiatry 2008, 63:475-483.
23. Graeber M.B., Li W., Rodriguez M.L. Role of microglia in CNS inflammation. FEBS Lett. 2011, 585:3798-3805.
24. Gunduz H., Wu H., Ashtari M., Bogerts B., Crandall D., Robinson D.G., Alvir J., Lieberman J., Kane J., Bilder R. Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects. Biol. Psychiatry 2002, 51:801-808.
25. Gur R.E., Maany V., Mozley P.D., Swanson C., Bilker W., Gur R.C. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am. J. Psychiatry 1998, 155:1711-1717.
26. Haijma S.V., Van H.N., Cahn W., Koolschijn P.C., Hulshoff Pol H.E., Kahn R.S. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr. Bull. 2013, 39:1129-1138.
27. Hertling I., Philipp M., Dvorak A., Glaser T., Mast O., Beneke M., Ramskogler K., Saletu-Zyhlarz G., Walter H., Lesch O.M. Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Neuropsychobiology 2003, 47:37-46.
28. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35:549-562.
29. Howes O.D., Montgomery A.J., Asselin M.C., Murray R.M., Valli I., Tabraham P., Bramon-Bosch E., Valmaggia L., Johns L., Broome M., McGuire P.K., Grasby P.M. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009, 66:13-20.
30. International Conference on Harmonization. ICH Harmonised Tripartite Guidelines for Good Clinical Practice 1996, Brookwood Medical Publications Ltd, Surrey.
31. Jacobs A.H., Tavitian B. Noninvasive molecular imaging of neuroinflammation. J. Cereb. Blood Flow Metab. 2012, 32:1393-1415.
32. Kay S.R., Fizbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-267.
33. Keshavan M.S., Rosenberg D., Sweeney J.A., Pettegrew J.W. Decreased caudate volume in neuroleptic-naive psychotic patients. Am. J. Psychiatry 1998, 155:774-778.
34. Koo M.S., Levitt J.J., McCarley R.W., Seidman L.J., Dickey C.C., Niznikiewicz M.A., Voglmaier M.M., Zamani P., Long K.R., Kim S.S., Shenton M.E. Reduction of caudate nucleus volumes in neuroleptic-naive female subjects with schizotypal personality disorder. Biol. Psychiatry 2006, 60:40-48.
35. Lang D.J., Kopala L.C., Vandorpe R.A., Rui Q., Smith G.N., Goghari V.M., Honer W.G. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. Am. J. Psychiatry 2001, 158:625-631.
36. Levitt J.J., McCarley R.W., Dickey C.C., Voglmaier M.M., Niznikiewicz M.A., Seidman L.J., Hirayasu Y., Ciszewski A.A., Kikinis R., Jolesz F.A., Shenton M.E. MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder. Am. J. Psychiatry 2002, 159:1190-1197.
37. Massana G., Salgado-Pineda P., Junque C., Perez M., Baeza I., Pons A., Massana J., Navarro V., Blanch J., Morer A., Mercader J.M., Bernardo M. Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. J. Clin. Psychopharmacol. 2005, 25:111-117.
38. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med. 2009, 39:1763-1777.
39. Nuechterlein K.H., Green M.F. MATRICS Consensus Battery Manual 2006, MATRICS Assessment Inc, Los Angeles.
40. Scherk H., Falkai P. Effects of antipsychotics on brain structure. Curr. Opin. Psychiatry 2006, 19:145-150.
41. Shihabuddin L., Buchsbaum M.S., Hazlett E.A., Haznedar M.M., Harvey P.D., Newman A., Schnur D.B., Spiegel-Cohen J., Wei T., Machac J., Knesaurek K., Vallabhajosula S., Biren M.A., Ciaravolo T.M., Luu-Hsia C. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Arch. Gen. Psychiatry 1998, 55:235-243.
42. Shihabuddin L., Buchsbaum M.S., Hazlett E.A., Silverman J., New A., Brickman A.M., Mitropoulou V., Nunn M., Fleischman M.B., Tang C., Siever L.J. Striatal size and relative glucose metabolic rate in schizotypal personality disorder and schizophrenia. Arch. Gen. Psychiatry 2001, 58:877-884.
43. Vita A., DePeri L. The effects of antipsychotic treatment on cerebral structure and function in schizophrenia. Int. Rev. Psychiatry 2007, 19:429-436.
44. Voelbel G.T., Bates M.E., Buckman J.F., Pandina G., Hendren R.L. Caudate nucleus volume and cognitive performance: are they related in childhood psychopathology? Biol. Psychiatry 2006, 60:942-950.
45. Zatorre R.J., Fields R.D., Johansen-Berg H. Plasticity in gray and white: neuroimaging changes in brain structure during learning. Nat. Neurosci. 2012, 15:528-536.